Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 111 clinical trials
Urinary T Cell Biomarker for Prediction in Lupus Nephritis

Urinary T-lymphocytes may be predictive for clinical outcome in patients with lupus nephritis. The investigators hypothesize that the amount of CD4+ effector/memory T-cells in urine at time of

nephritis
  • 35 views
  • 24 Jan, 2021
  • 2 locations
Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis

This is an open-label, prospective, single-arm, observational study in patients with Lupus nephritis (LN) who newly (i.e.,for the first time) received treatment of Enteric-coated Mycophenolate

  • 0 views
  • 02 May, 2021
  • 2 locations
Effect of Urine Alkalinazation on Urinary Inflammatory Markers in Patients With Cystinuria

It has recently been described the presence of a urinary inflammatory signature in patients with cystinuria, the most common cause of renal lithiasis of genetical origin. These data are very innovative in this pathology but deserve further studies to establish the specificity of this inflammatory signature in patients with cystinuria …

  • 0 views
  • 22 Jan, 2021
The Canadian Glomerulonephritis Registry and Translational Research Initiative

Glomerulonephritis (GN) is one of the most important causes of kidney failure in Canada. These comprise a group of "rare" diseases (<5 per 250,000 population), yet GN is a leading cause of kidney failure and accounts annually for close to 20% of incident cases of end stage kidney disease (ESKD) …

kidney biopsy
mpgn
nephropathy
anca
focal segmental glomerulosclerosis
  • 11 views
  • 22 Jan, 2021
  • 1 location
Identifying New Therapeutic Targets for Lupus Treatment

Lupus is an autoimmune disease affecting mainly young women (9/1). Lupus nephritis (LN) occurs in 30% of the cases of lupus and is associated with end stage renal disease (ESRD) in 17 to 25% of

remission
corticosteroids
nephropathy
autoimmune disease
nephritis
  • 17 views
  • 26 Jan, 2021
  • 2 locations
Serological and Urinary Biomarkers in Latin American Patients With Systemic Lupus Erythematosus: GLADEL 2.0 Cohort

Lupus nephritis (LN) is one of the main manifestationsin SLE patients, having an important impact on morbidity and mortality. Renal biopsy is the "gold standard" for the diagnosis of LN, however

anti-dna antibodies
calcineurin inhibitors
nephritis
systemic lupus erythematosus
  • 7 views
  • 07 May, 2021
  • 1 location
Urinary T Lymphocytes Predict Renal Flares in Patients With Inactive ANCA-associated Glomerulonephritis

Urinary CD4+ and CD8+ T lymphocytes may predict renal flares in patients with inactive ANCA-associated vasculitis and thus serve as early non-invasive biomarkers. Urine samples of patients with inactive renal ANCA-vasculitis will be analysed by flow cytometry and compared to clinical outcome after 6 months.

proteinuria
anca
  • 0 views
  • 24 Jan, 2021
  • 2 locations
European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome

The hereditary type IV collagen disease Alport syndrome inevitably leads to end-stage renal disease. Currently there are no therapies known to improve outcome. Our non-interventional, observational study investigates, if medications such as ACE-inhibitors can (1) delay time to dialysis and (2) improve life-expectancy within three generations of Alport-families in Europe.

  • 81 views
  • 09 May, 2021
  • 1 location
Improving Renal Complications in Adolescents With Type 2 Diabetes Through REsearch Cohort Study (National iCARE Study)

>Determine if systemic and renal inflammation is the common pathway through which BPS risk factors lead to albuminuria in youth with T2D. Study Hypotheses include: Biological

insulin resistance
type 2 diabetes mellitus
hypertension
renal injury
fasting
  • 3 views
  • 27 Jan, 2021
  • 1 location
A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)

The purpose of this Phase 2 adaptive study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of PF-06730512 following multiple intravenous infusion in adult subjects with FSGS.

total protein
glomerular filtration rate
focal segmental glomerulosclerosis
tubulointerstitial fibrosis
immunosuppressive agents
  • 226 views
  • 30 Apr, 2021
  • 93 locations